## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%); PEG 4.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($162.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Corient Private Wealth LLC Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ**
- Source: MarketBeat | 20251228T090916 | Neutral | Relevance: 100%
- Corient Private Wealth LLC significantly reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 52.8% in Q2 2025, selling 7,189 shares and ending the quarter with 6,437 shares valued at $669,000. Despite this, Jazz Pharmaceuticals holds a "Moderate Buy" consensus rating from analysts with an average price target of $200.47, indicating potential upside. Company insiders have been net sellers, offloading shares worth $22.7 million in the last three months, though they still retain about 4.3% ownership.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($5.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Valuation stretched: PEG 4.0x requires aggressive growth execution.
3. Elevated short interest (9.6%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.02 signals overvaluation risk, limited margin of safety. Forward P/E 7.6x attractive for 179% earnings growth. Analyst sentiment positive (1 raises, avg +49%). Insider selling cluster ($5.0M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.4B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.02 |
| Forward P/E | 7.6 |
| Current P/E | 21.1 |
| YoY Growth | 179.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 2.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.56), momentum weakening. RSI neutral at 60. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.69% (CS: 77) | Neutral |
| RSI_14 | 59.9 | Neutral |
| MACD Histogram | -0.56 | Bearish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.086x | Above |
| vs SMA200 | 1.338x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $170.82
- **Stop Loss:** $162.52 (4.9% risk)
- **Target:** $179.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 159
- **Position Value:** $27,160.38
- **Portfolio %:** 27.16%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*